Raajit Rampal
@raajitrampal.bsky.social
Physician-Scientist investigating and treating Myeloproliferative Neoplasms and Acute Myeloid Leukemia.
Reposted by Raajit Rampal
Glad to share the finalized version of a Haematologica review by @raajitrampal.bsky.social and me focused on accelerated/blast-phase MPNs!
haematologica.org/article/view...
haematologica.org/article/view...
April 1, 2025 at 3:05 PM
Glad to share the finalized version of a Haematologica review by @raajitrampal.bsky.social and me focused on accelerated/blast-phase MPNs!
haematologica.org/article/view...
haematologica.org/article/view...
Out today in
@NatureMedicine
phase 3 data from thh MANIFEST-2 study nature.com/articles/s41...
@aarongerds.bsky.social @mpndoc.bsky.social @kuykendallmd.bsky.social @rubenmesamd.bsky.social
@NatureMedicine
phase 3 data from thh MANIFEST-2 study nature.com/articles/s41...
@aarongerds.bsky.social @mpndoc.bsky.social @kuykendallmd.bsky.social @rubenmesamd.bsky.social
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial - Nature Medicine
In a randomized phase 3 trial, the combination of the BET inhibitor pelabresib with the JAK inhibitor ruxolitinib resulted in a significantly higher spleen volume reduction from baseline versus placeb...
nature.com
March 10, 2025 at 7:36 PM
Out today in
@NatureMedicine
phase 3 data from thh MANIFEST-2 study nature.com/articles/s41...
@aarongerds.bsky.social @mpndoc.bsky.social @kuykendallmd.bsky.social @rubenmesamd.bsky.social
@NatureMedicine
phase 3 data from thh MANIFEST-2 study nature.com/articles/s41...
@aarongerds.bsky.social @mpndoc.bsky.social @kuykendallmd.bsky.social @rubenmesamd.bsky.social
Reposted by Raajit Rampal
@mskcancercenter.bsky.social cycle for survival! Time to ride and raise money for rare cancers
February 8, 2025 at 1:58 PM
@mskcancercenter.bsky.social cycle for survival! Time to ride and raise money for rare cancers
Reposted by Raajit Rampal
1. Today the NIH director issued a new directive slashing overhead rates to 15%.
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
grants.nih.gov
February 8, 2025 at 12:18 AM
1. Today the NIH director issued a new directive slashing overhead rates to 15%.
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
Reposted by Raajit Rampal
Important report in @nejm.org from @mskcancercenter.bsky.social CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 #CARTcells #mmsm www.nejm.org/doi/full/10....
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy
has been described, but the contribution of CAR integration to oncogenesis is not
clear. Here we report a case o...
www.nejm.org
February 7, 2025 at 1:24 AM
Important report in @nejm.org from @mskcancercenter.bsky.social CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 #CARTcells #mmsm www.nejm.org/doi/full/10....
I just registered for Cycle for Survival to support MPN research at MSKCC. My ride is March 7 and I’m trying to raise as much as I can by then to help people with MPNs Make your 100% tax-deductible donation here secure2.convio.net/mskcc/site/T...
Cycle for Survival: The Movement to Beat Rare Cancers
Support rare cancer research at Memorial Sloan Kettering Cancer Center.
secure2.convio.net
February 6, 2025 at 8:47 PM
I just registered for Cycle for Survival to support MPN research at MSKCC. My ride is March 7 and I’m trying to raise as much as I can by then to help people with MPNs Make your 100% tax-deductible donation here secure2.convio.net/mskcc/site/T...
Reposted by Raajit Rampal
#REVIEW
Vallot, Lupien and Lasine describe how epigenomic heterogeneity generates dynamic reservoirs of tumour cell states, which can be leveraged in the design of novel therapies.
📖 👉 https://bit.ly/40PCQ...
Vallot, Lupien and Lasine describe how epigenomic heterogeneity generates dynamic reservoirs of tumour cell states, which can be leveraged in the design of novel therapies.
📖 👉 https://bit.ly/40PCQ...
Epigenomic heterogeneity as a source of tumour evolution - Nature Reviews Cancer
Single-cell epigenomic technologies are refining our understanding of cancer evolution.
bit.ly
January 27, 2025 at 3:13 PM
#REVIEW
Vallot, Lupien and Lasine describe how epigenomic heterogeneity generates dynamic reservoirs of tumour cell states, which can be leveraged in the design of novel therapies.
📖 👉 https://bit.ly/40PCQ...
Vallot, Lupien and Lasine describe how epigenomic heterogeneity generates dynamic reservoirs of tumour cell states, which can be leveraged in the design of novel therapies.
📖 👉 https://bit.ly/40PCQ...